Response to the letter titled “Comment on associations of semaglutide with first‐time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real‐world data in the US”
Year: 2025
Type: article
Abstract: benefits for AD prevention, particularly in high-risk populations.We strongly encourage future randomized clinical trials to confirm these findings and clarify the causal
Source: Alzheimer s & Dementia
DOI: 10.1002/alz.14581
Author: Rong Xu
Institution: Case Western Reserve University
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,200
OpenAlex ID: W4410333757